Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma.
Benjamin M EllingsonKunal PatelChencai WangCatalina RaymondAndrew BrennerJohn F de GrootNicholas A ButowskiLeor ZachJian L CampianJacob SchlossmanShan RizviYael C CohenNoa Lowenton-SpierTamar Rachmilewitz MineiShifra Fain ShmueliPatrick Y WenTimothy F CloughesyPublished in: Neuro-oncology advances (2021)
Baseline diffusion MRI and tumor volume are independent imaging biomarkers of OS in rGBM treated with BV or BV+VB-111.
Keyphrases
- phase iii
- open label
- clinical trial
- double blind
- contrast enhanced
- placebo controlled
- phase ii
- magnetic resonance imaging
- lipopolysaccharide induced
- lps induced
- diffusion weighted imaging
- high resolution
- inflammatory response
- computed tomography
- magnetic resonance
- metastatic colorectal cancer
- newly diagnosed
- mass spectrometry